Rachel E Rosenblum1, Celina Ang2, Sabrina A Suckiel3,4, Emily R Soper3,4, Meenakshi R Sigireddi5, Sinead Cullina3, Gillian M Belbin3,6, Aimee L Lucas7, Eimear E Kenny3,5,6, Noura S Abul-Husn3,4,5,6. 1. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. 2. Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. 3. The Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY. 4. Division of Genomic Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. 5. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY. 6. Division of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. 7. Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Abstract
PURPOSE: Limited data are available on the prevalence and clinical impact of Lynch syndrome (LS)-associated genomic variants in non-European ancestry populations. We identified and characterized individuals harboring LS-associated variants in the ancestrally diverse BioMe Biobank in New York City. PATIENTS AND METHODS: Exome sequence data from 30,223 adult BioMe participants were evaluated for pathogenic, likely pathogenic, and predicted loss-of-function variants in MLH1, MSH2, MSH6, and PMS2. Survey and electronic health record data from variant-positive individuals were reviewed for personal and family cancer histories. RESULTS: We identified 70 individuals (0.2%) harboring LS-associated variants in MLH1 (n = 12; 17%), MSH2 (n = 13; 19%), MSH6 (n = 16; 23%), and PMS2 (n = 29; 41%). The overall prevalence was 1 in 432, with higher prevalence among individuals of self-reported African ancestry (1 in 299) than among Hispanic/Latinx (1 in 654) or European (1 in 518) ancestries. Thirteen variant-positive individuals (19%) had a personal history, and 19 (27%) had a family history of an LS-related cancer. LS-related cancer rates were highest in individuals with MSH6 variants (31%) and lowest in those with PMS2 variants (7%). LS-associated variants were associated with increased risk of colorectal (odds ratio [OR], 5.0; P = .02) and endometrial (OR, 30.1; P = 8.5 × 10-9) cancers in BioMe. Only 2 variant-positive individuals (3%) had a documented diagnosis of LS. CONCLUSION: We found a higher prevalence of LS-associated variants among individuals of African ancestry in New York City. Although cancer risk is significantly increased among variant-positive individuals, the majority do not harbor a clinical diagnosis of LS, suggesting underrecognition of this disease.
PURPOSE: Limited data are available on the prevalence and clinical impact of Lynch syndrome (LS)-associated genomic variants in non-European ancestry populations. We identified and characterized individuals harboring LS-associated variants in the ancestrally diverse BioMe Biobank in New York City. PATIENTS AND METHODS: Exome sequence data from 30,223 adult BioMe participants were evaluated for pathogenic, likely pathogenic, and predicted loss-of-function variants in MLH1, MSH2, MSH6, and PMS2. Survey and electronic health record data from variant-positive individuals were reviewed for personal and family cancer histories. RESULTS: We identified 70 individuals (0.2%) harboring LS-associated variants in MLH1 (n = 12; 17%), MSH2 (n = 13; 19%), MSH6 (n = 16; 23%), and PMS2 (n = 29; 41%). The overall prevalence was 1 in 432, with higher prevalence among individuals of self-reported African ancestry (1 in 299) than among Hispanic/Latinx (1 in 654) or European (1 in 518) ancestries. Thirteen variant-positive individuals (19%) had a personal history, and 19 (27%) had a family history of an LS-related cancer. LS-related cancer rates were highest in individuals with MSH6 variants (31%) and lowest in those with PMS2 variants (7%). LS-associated variants were associated with increased risk of colorectal (odds ratio [OR], 5.0; P = .02) and endometrial (OR, 30.1; P = 8.5 × 10-9) cancers in BioMe. Only 2 variant-positive individuals (3%) had a documented diagnosis of LS. CONCLUSION: We found a higher prevalence of LS-associated variants among individuals of African ancestry in New York City. Although cancer risk is significantly increased among variant-positive individuals, the majority do not harbor a clinical diagnosis of LS, suggesting underrecognition of this disease.
Authors: Francis M Giardiello; John I Allen; Jennifer E Axilbund; C Richard Boland; Carol A Burke; Randall W Burt; James M Church; Jason A Dominitz; David A Johnson; Tonya Kaltenbach; Theodore R Levin; David A Lieberman; Douglas J Robertson; Sapna Syngal; Douglas K Rex Journal: Gastroenterology Date: 2014-08 Impact factor: 22.682
Authors: Laura Baglietto; Noralane M Lindor; James G Dowty; Darren M White; Anja Wagner; Encarna B Gomez Garcia; Annette H J T Vriends; Nicola R Cartwright; Rebecca A Barnetson; Susan M Farrington; Albert Tenesa; Heather Hampel; Daniel Buchanan; Sven Arnold; Joanne Young; Michael D Walsh; Jeremy Jass; Finlay Macrae; Yoland Antill; Ingrid M Winship; Graham G Giles; Jack Goldblatt; Susan Parry; Graeme Suthers; Barbara Leggett; Malinda Butz; Melyssa Aronson; Jenny N Poynter; John A Baron; Loic Le Marchand; Robert Haile; Steve Gallinger; John L Hopper; John Potter; Albert de la Chapelle; Hans F Vasen; Malcolm G Dunlop; Stephen N Thibodeau; Mark A Jenkins Journal: J Natl Cancer Inst Date: 2009-12-22 Impact factor: 13.506
Authors: Sining Chen; Wenyi Wang; Shing Lee; Khedoudja Nafa; Johanna Lee; Kathy Romans; Patrice Watson; Stephen B Gruber; David Euhus; Kenneth W Kinzler; Jeremy Jass; Steven Gallinger; Noralane M Lindor; Graham Casey; Nathan Ellis; Francis M Giardiello; Kenneth Offit; Giovanni Parmigiani Journal: JAMA Date: 2006-09-27 Impact factor: 56.272
Authors: Michel De Vos; Bruce E Hayward; Susan Picton; Eamonn Sheridan; David T Bonthron Journal: Am J Hum Genet Date: 2004-04-07 Impact factor: 11.025
Authors: Miriam J Smith; Jill E Urquhart; Elaine F Harkness; Emma K Miles; Naomi L Bowers; Helen J Byers; Michael Bulman; Carolyn Gokhale; Andrew J Wallace; William G Newman; D Gareth Evans Journal: Hum Mutat Date: 2016-01-11 Impact factor: 4.878
Authors: Rodrigo Santa Cruz Guindalini; Aung Ko Win; Cassandra Gulden; Noralane M Lindor; Polly A Newcomb; Robert W Haile; Victoria Raymond; Elena Stoffel; Michael Hall; Xavier Llor; Chinedu I Ukaegbu; Ilana Solomon; Jeffrey Weitzel; Matthew Kalady; Amie Blanco; Jonathan Terdiman; Gladis A Shuttlesworth; Patrick M Lynch; Heather Hampel; Henry T Lynch; Mark A Jenkins; Olufunmilayo I Olopade; Sonia S Kupfer Journal: Gastroenterology Date: 2015-08-03 Impact factor: 22.682
Authors: Sophia H L George; Talia Donenberg; Cheryl Alexis; Vincent DeGennaro; Hedda Dyer; Sook Yin; Jameel Ali; Raleigh Butler; Sheray N Chin; DuVaughn Curling; Dwight Lowe; John Lunn; Theodore Turnquest; Gilian Wharfe; Danielle Cerbon; Priscila Barreto-Coelho; Matthew P Schlumbrecht; Mohammad R Akbari; Steven A Narod; Judith E Hurley Journal: JAMA Netw Open Date: 2021-03-01